Publications by authors named "Bjoern O Schelter"

Claim this Profile
I
Inferring the underlying multivariate structure from bivariate networks with highly correlated nodes.
Philipp Loske, Bjoern O Schelter

Sci Rep· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Hydromethylthionine Treatment Is Associated with Delayed Clinical Onset and Slowing of Cerebral Atrophy in a Pre-Symptomatic P301S MAPT Mutation Carrier.
Peter Bentham, Roger T Staff, Bjoern O Schelter, Helen Shiells, Charles R Harrington

J Alzheimers Dis· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia.
Helen Shiells, Bjoern O Schelter, Peter Bentham, Thomas C Baddeley, Christopher M Rubino

J Alzheimers Dis· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concentration-Dependent Activity of Hydromethylthionine on Cognitive Decline and Brain Atrophy in Mild to Moderate Alzheimer's Disease.
Bjoern O Schelter, Helen Shiells, Thomas C Baddeley, Christopher M Rubino, Harish Ganesan

J Alzheimers Dis· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial.
Gordon K Wilcock, Serge Gauthier, Giovanni B Frisoni, Jianping Jia, Jiri H Hardlund, Bjoern O Schelter

J Alzheimers Dis· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial.
Serge Gauthier, Howard H Feldman, Lon S Schneider, Gordon K Wilcock, Giovanni B Frisoni, Bjoern O Schelter

Lancet· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis